Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study
BACKGROUND: Real-world evidence on the comparative effectiveness of pegfilgrastim
biosimilars compared with the originator product is limited. OBJECTIVE: To compare the risk …
biosimilars compared with the originator product is limited. OBJECTIVE: To compare the risk …
Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially …
BACKGROUND: It is unknown whether using pegfilgrastim biosimilars is cost saving in a
real-world setting. OBJECTIVE: To compare medical costs including pegfilgrastim drug costs …
real-world setting. OBJECTIVE: To compare medical costs including pegfilgrastim drug costs …
Biosimilar pegfilgrastim: improving access and optimising practice to supportive care that enables cure
P Cornes, P Gascon, AG Vulto, M Aapro - BioDrugs, 2020 - Springer
Febrile neutropenia (FN) is a serious complication of chemotherapy, which can cause
significant morbidity and mortality, result in dose delays and reductions and, ultimately …
significant morbidity and mortality, result in dose delays and reductions and, ultimately …
Real-world cost–effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia
P Cornes, J Kelton, R Liu, O Zaidi, J Stephens… - Future …, 2022 - Future Medicine
Background: Real-world data suggests superiority of pegfilgrastim (PEG) over filgrastim (FIL)
in reducing the incidence of chemotherapy-induced febrile neutropenia (FN), probably …
in reducing the incidence of chemotherapy-induced febrile neutropenia (FN), probably …
Pegfilgrastim biosimilars in US supportive oncology: a narrative review of administration options and economic considerations to maximize patient benefit
SZ Humphreys, RB Geller, P Walden - Oncology and Therapy, 2022 - Springer
Granulocyte colony-stimulating factor (G-CSF) biologics, such as pegfilgrastim, are a
standard of care in supportive cancer treatment that are administered once per …
standard of care in supportive cancer treatment that are administered once per …
Cost comparison of filgrastim versus pegfilgrastim and pegfilgrastim biosimilars for inpatient prophylaxis of febrile neutropenia
K Singer, CM Forshay… - Journal of Oncology …, 2023 - journals.sagepub.com
Introduction The Ohio State University Comprehensive Cancer Center (The James) uses
daily subcutaneous filgrastim as the inpatient granulocyte colony-stimulating factor of …
daily subcutaneous filgrastim as the inpatient granulocyte colony-stimulating factor of …
Efficacy and safety of filgrastim and its biosimilars to prevent febrile neutropenia in cancer patients: a prospective study and meta-analysis
Simple Summary Febrile neutropenia is the serious side-effect associated with
myelosuppressive chemotherapy. Filgrastim, the first granulocyte colony-stimulating factor …
myelosuppressive chemotherapy. Filgrastim, the first granulocyte colony-stimulating factor …
Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US …
K Desai, P Misra, S Kher, N Shah - Experimental Hematology & Oncology, 2018 - Springer
Background Chemotherapy-induced neutropenia is a common result of myelosuppressive
chemotherapy treatment. Infections such as febrile neutropenia (FN) are sensitive to the …
chemotherapy treatment. Infections such as febrile neutropenia (FN) are sensitive to the …
A comparison of brand and biosimilar granulocyte-colony stimulating factors for prophylaxis of chemotherapy-induced febrile neutropenia
AG Douglas, P Schwab, D Lane, K Kennedy… - Journal of Managed …, 2017 - jmcp.org
BACKGROUND: Filgrastim-sndz, a granulocyte-colony stimulating factor (G-CSF), was
introduced as a biosimilar to filgrastim in 2015, but real-world comparative effectiveness for …
introduced as a biosimilar to filgrastim in 2015, but real-world comparative effectiveness for …
Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia
AR Zullo, U Lou, SE Cabral, J Huynh… - Journal of Oncology …, 2019 - journals.sagepub.com
Introduction Guidelines recommend pegfilgrastim for primary prophylaxis of febrile
neutropenia after highly myelosuppressive chemotherapy. While deviations from guidelines …
neutropenia after highly myelosuppressive chemotherapy. While deviations from guidelines …